What is BenchSci?
Founded in 2015 and headquartered in Toronto, BenchSci provides an advanced software platform specifically engineered to optimize antibody selection and preclinical research workflows. By leveraging machine learning and natural language processing, the company enables scientists to navigate vast amounts of experimental data, significantly reducing the time and cost associated with drug development. BenchSci occupies a vital niche in the biotech ecosystem, acting as a bridge between complex biological data and actionable research insights. Its market position is bolstered by its ability to integrate seamlessly into existing laboratory workflows, thereby enhancing the efficiency of research and development teams at major pharmaceutical organizations worldwide.
How much funding has BenchSci raised?
BenchSci has raised a total of $163M across 4 funding rounds:
Series A
$8M
Series B
$22M
Series C
$63M
Series D
$70M
Series A (2018): $8M, investors not publicly disclosed
Series B (2020): $22M led by Fidelity
Series C (2022): $63M supported by Technology Crossover Ventures and Inovia
Series D (2023): $70M featuring Technology Crossover Ventures, Inovia, and Generation Investment Management
Key Investors in BenchSci
Technology Crossover Ventures
Technology Crossover Ventures is a Menlo Park-based firm established in 1995 that specializes in late-stage growth equity, acquisitions, and recapitalization strategies for technology-driven enterprises.
Inovia
iNovia Capital is a full-stack venture firm founded in 2007 that partners with founders to build enduring global technology companies through a people-first investment philosophy.
Generation Investment Management
Generation Investment Management focuses on mobilizing capital to address climate change and sustainability, seeking to unlock the potential of markets to create a more equitable economic system.
What's next for BenchSci?
With the successful closure of its latest funding round, BenchSci is well-positioned to scale its enterprise-level operations and further refine its proprietary AI models. The strategic focus will likely shift toward expanding its product suite to cover broader areas of preclinical research, potentially moving beyond antibody selection into more diverse therapeutic modalities. As the company matures, it will likely prioritize global market penetration and the strengthening of its partnerships with top-tier pharmaceutical firms. The influx of capital provides the necessary runway to invest in top-tier talent and infrastructure, ensuring that BenchSci remains at the forefront of the digital transformation within the life sciences industry. Investors will be closely monitoring the company's ability to maintain its growth momentum while navigating the complexities of the global biotech market.
See full BenchSci company page
